Related Experiment Video
Updated: May 13, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
In Silico Comparison of Photon Versus Proton Based Stereotactic Body Radiotherapy With Increasing Maximum Peak Dose
Sherif G Shaaban1, Hao Chen2, Anh Tran1
1Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Purpose:
Photon based Stereotactic Body Radiotherapy (PH-SBRT) has emerged as a promising option for treatment of primary renal cell carcinoma (RCC), however is associated with decrements in long-term kidney function and toxicity to adjacent organs at risk (OARs).
Materials And Methods:
We compared proton (PT) based SBRT versus PH-SBRT regarding target coverage, OARs, and maximum peak doses of 125% and 142%. All variables were compared using student t-tests.
Results:
Target coverage was comparable between plans for gross tumor volume (GTV) and clinical target volume (CTV). OARs were greatly spared by PT-SBRT including small bowel; V5 Gy to V25 Gy and maximum dose (10.47, 20.22, P = .02), large bowel; V5 Gy to V25 Gy and maximum dose (16.16, 23.90, P = .03), all volumes of uninvolved ipsilateral kidney and maximum dose to heart, lungs, esophagus, stomach, duodenum, ipsilateral ureter, and spinal canal. The ratio of ipsilateral kidney V50%/Vtot (volume receiving 50% of the dose/total volume), which is correlated with glomerular filtration rate loss in prospective trials, was significantly lower with PT-SBRT for both maximum dose of 125% (25.41, 19.97, P < .01) and 142% (23.33, 19.18, P < .01). Integral dose was significantly lower with protons. PT-SBRT with higher peak dose allowed for additional sparing of OARs: stomach V 10 Gy, liver V 25 Gy, large bowel V 30 Gy, V 35 Gy, ipsilateral kidney cortex.
Conclusion:
PT-SBRT improved target coverage while reducing dose to the involved kidney and adjacent OARs. Protons allow delivery of maximum peak dose escalated plans without exceeding the normal tissues limit and have the potential to better preserve renal function. Prospective studies are warranted to validate these findings and potential clinical benefits.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy